Entera Bio (NASDAQ:ENTX) Releases Earnings Results, Beats Expectations By $0.02 EPS

Entera Bio (NASDAQ:ENTX) released its quarterly earnings data on Friday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02, Zacks reports.

Entera Bio Stock Up 9.7%

ENTX stock opened at $1.13 on Friday. Entera Bio has a fifty-two week low of $0.98 and a fifty-two week high of $3.22. The firm’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $1.89. The stock has a market cap of $51.82 million, a PE ratio of -4.35 and a beta of 1.83.

Insider Transactions at Entera Bio

In other news, Director Geno J. Germano bought 20,000 shares of Entera Bio stock in a transaction on Monday, March 9th. The stock was purchased at an average cost of $1.30 per share, with a total value of $26,000.00. Following the purchase, the director directly owned 40,000 shares of the company’s stock, valued at approximately $52,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 69,000 shares of company stock worth $92,530. Insiders own 10.38% of the company’s stock.

Hedge Funds Weigh In On Entera Bio

Several hedge funds and other institutional investors have recently made changes to their positions in ENTX. Superstring Capital Management LP bought a new position in Entera Bio in the 4th quarter worth approximately $33,000. Renaissance Technologies LLC raised its stake in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares in the last quarter. HighTower Advisors LLC boosted its position in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares during the period. Citadel Advisors LLC grew its stake in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after purchasing an additional 29,629 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ENTX shares. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research note on Monday, February 9th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.